Konference: 2008 IV. ročník DDPEO A I. ročník sympózia O cílené biologické léčbě
Kategorie:
Nádorová biologie/imunologie/genetika a buněčná terapie
Téma: Molekulární podstata účinku protinádorových léčiv
Číslo abstraktu: 006
Autoři: Madhusudhan Reddy Kollareddy; doc. MUDr. Marián Hajdúch, Ph.D.; MUDr. Petr Džubák
Retinoblastoma protein (pRb) is a well
characterized tumor suppressor protein. pRb in association with
other protein binding partners is involved in G1 check point
regulation. This check point ensures that cells have attained
enough size and harbors sufficient nutrients before they enter into
replication phase. pRb governing G1 check point is also activated
upon exposure to cytotoxic agents (anticancer compounds) that
induce apotosis. During apoptosis pRb is dephosphorylated resulting
in cell cycle arrest and subsequently cleaved sequentially in
response to cytotoxic agents. Here we present the differential
cleavage pattern of pRb upon exposure to different class of
anticancer compounds that induce apoptosis. This cleavage pattern
may result due to the action of different effector caspases that
recognizes specific consensus sequences of pRb. A particular type
of sequential pRb cleavage induced by a specific cytotoxic agent
may have advantage of an increased rate of apoptosis and subsequent
rapid tumor clearance. Hence this small study may help to select
the efficient anticancer compounds that induce specific pRb
cleavage, which inturn enhance the rate of apoptosis rapidly
compared to other cytotoxic agents that induce different type of
pRb cleavage pattern.
Práce je podporována granty: MSM 6198959216 a
LC07017.
Datum přednesení příspěvku: 26. 11. 2008